For years, high cancer diagnosis rates and limited access to quality health services plagued the Navajo residents cared for by the Tséhootsooí Medical Center in Fort Defiance, Arizona. 


Increasing research on women with dense breasts is having a positive effect on imaging modalities. It is estimated that between 30–40 percent of women in the United States have dense breasts. Because fatty breast tissue makes it difficult to identify breast tumors on standard mammography exams until very advanced stages, dense breasts are a strong independent factor for breast cancer. Research has shown that it is beneficial for this population of women to invest in additional imaging. 



Defining disease processes by their cellular and molecular signatures has enabled molecular diagnosis and the development of targeted therapies, and advances in genomics offer promise for earlier disease detection and possibly molecular prevention. The field of molecular imaging is embracing these advances and is using a diverse set of molecular imaging strategies to interrogate disease states and physiology.


In early February, the Centers for Medicare and Medical Services (CMS) announced a final rule necessary to implement requirements laid out in the Affordable Care Act Sunshine Rule that will increase public disclosure of financial relationships between drug/device manufacturers, and physicians and teaching hospitals.

For better treatment planning during cardiac resynchronization therapy (CRT), Toshiba America Medical System Inc.’s Activation Imaging is the company’s latest addition to its 3-D Wall Motion Tracking software. Activation Imaging is an U.S. Food and Drug Administration (FDA)-cleared, proprietary technology available on the Aplio Artida cardiovascular ultrasound system.

 

Activation Imaging Technology

Subscribe Now